# Impact of immune checkpoint inhibition on ovarian reserve

## TL;DR

This study examines how immune checkpoint inhibitors affect ovarian reserve in young women with melanoma, finding a reduction in a key hormone.

## Contribution

The study is the first to show a potential impact of ICI on ovarian reserve markers in young women with melanoma.

## Key findings

- Anti-Mullerian hormone levels decreased in patients treated with ICI.
- Similar reductions were observed in patients receiving targeted therapy.
- The findings highlight the need for further research on fertility impacts of these therapies.

## Abstract

Immune checkpoint inhibition (ICI) has become a mainstay of therapy for various types of malignancy and is being used earlier in the course of therapy. In addition, there are many young women diagnosed with cancers for whom ICI is the standard of care. However, the impact of ICI on fertility is unknown and hard to assess. To evaluate this, we performed an analysis of hormones associated with ovarian reserve in young women with melanoma treated with ipilimumab. Our study showed a reduction in anti-Mullerian hormone, a marker of ovarian reserve, in patients with melanoma treated with either ICI or targeted therapy. These results support the need for further work in this area to better understand the impact these therapies have on fertility.